APTOF · As filed with the SEC
Aptose Biosciences cash flow statement, by quarter
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025† 3 months ended Sep 30, 2025 | Q2 2025† 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income | (7,634,000) | — | — | — |
| Adjustments to reconcile net loss to cash used in operating activities: | ||||
| Stock-based compensation | 129,000 | — | — | — |
| Depreciation of property and equipment | 2,000 | — | — | — |
| Noncash operating lease expense | 104,000 | — | — | — |
| Interest on lease liabilities | 3,000 | — | — | — |
| Interest on loan payable to related party | 433,000 | — | — | — |
| Unrealized gain on short-term investment | 0 | — | — | — |
| Change in operating assets and liabilities: | ||||
| Prepaid expenses | 364,000 | — | — | — |
| Other assets | (1,172,000) | — | — | — |
| Change in operating lease liability | (116,000) | — | — | — |
| Accounts payable | 899,000 | — | — | — |
| Accrued liabilities | 1,147,000 | — | — | — |
| Cash used in operating activities | (5,841,000) | — | — | — |
| Cash flows from investing activities: | ||||
| Disposal of property and equipment | — | 0† | 0† | 0† |
| Cash provided by investing activities | 0 | — | — | — |
| Cash flows from financing activities: | ||||
| Proceeds from loan payable with related party | 5,850,000 | — | — | — |
| Repayment of loan with related party | — | 0† | 0† | — |
| The 2025 ATM Offering | 0 | — | — | — |
| ESPP | 0 | — | — | — |
| Cash provided by financing activities | 5,850,000 | — | — | — |
| Effect of exchange rate fluctuations on cash | 0 | — | — | — |
| Increase (decrease) in cash and restricted cash | 9,000 | — | — | — |
| Cash and restricted cash, beginning of period | 4,096,000 | 1,637,000 | 1,298,000 | 4,743,000 |
| Cash and restricted cash, end of period | 4,105,000 | 4,096,000 | 1,637,000 | 1,298,000 |
| Supplemental disclosures of non-cash financing activities: | ||||
| Conversion of loan payable with related party to common shares | 0 | — | — | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.